Question explored with the scientific record
Conversation so far
- 1 Specifically does Met foreign help injured heart tissue
- 2 Gardiance help injured heart tissue
Answered on this page ↓
Gardiance help injured heart tissue
Empagliflozin (Jardiance) does not repair injured heart muscle. It reduces hospitalizations and deaths in people whose hearts are already failing.
The strongest human evidence is in hospitalized acute heart failure: 530 patients, 90 days, deaths 11 of 265 on empagliflozin versus 22 of 265 on placebo, and heart failure events 28 versus 39 [1]. In chronic heart failure with reduced pumping, the primary composite fell from 24.7% to 19.4% [2][4]. Those are hard outcomes, not lab values. But the benefit is fewer events and fewer deaths, not regrown or healed tissue.
| Trial population | Outcome | Empagliflozin | Placebo |
|---|---|---|---|
| Acute HF, hospitalized [1] | Deaths at 90 days | 11 of 265 | 22 of 265 |
| Acute HF, hospitalized [1] | HF events at 90 days | 28 of 265 | 39 of 265 |
| Chronic HFrEF [2][4] | CV death or HF hospitalization | 19.4% | 24.7% |
| HFpEF (EMPEROR-Preserved) [3] | CV death or HF hospitalization | HR 0.79 | reference |
| HFpEF (EMPEROR-Preserved) [3] | CV death alone | not significantly reduced | reference |
On actual tissue repair, the human data are thin. A 12-week trial in diabetics with stiff hearts improved a filling-pressure measure (E/e′) by 1.18 [8]. That is a surrogate, not proof of healing. The repair story rests mostly on mice: empagliflozin cut scar collagen 54.2% and superoxide 44.4% after pressure overload [9]. Mouse remodeling data have a long record of not carrying over to people.
The one direct test after a heart attack found no reduction in worsening heart failure when started within 14 days in patients with ejection fraction under 45% [7]. A dedicated trial testing whether empagliflozin limits infarct size and no-reflow during a heart attack is still only a protocol, not results [5].
The harms are real but mostly manageable: genital fungal infections run 3 to 4 times higher than placebo [6], and rare ketoacidosis and Fournier gangrene occur [7]. Most of these trials were run by the manufacturers, and none of the retrieved records shows the drug regrowing damaged heart muscle.
My call: empagliflozin helps people with failing hearts live longer and stay out of the hospital, but it does not heal injured heart tissue, and the repair claims rest on mouse data and surrogate measures. Confidence: moderate on the outcome benefit, low on any tissue-repair claim.
Sources used 9
-
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
The study investigates the efficacy and safety of the SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure, demonstrating significant clinical benefits in reducing mortality and heart failure events over 90 days compared to placebo.
DOI: 10.1038/s41591-021-01659-1 -
P003. An Evidence Based Quality Improvement Project of the Impact of a Nurse Practitioner Led Heart Failure, Self-Care Focused, Patient Education on Healthcare Related Quality of Life
This study investigates the effects of empagliflozin on cardiovascular and renal outcomes in patients with heart failure, demonstrating a significant reduction in the risk of cardiovascular death and hospitalization for heart failure compared to placebo.
DOI: 10.1016/j.hrtlng.2021.03.058 -
Sglt-2 Inhibitors: A Useful Addition for Treatment of Heart Failure with Mildly Preserved and Preserved Ejection Fraction
A critical review of the role of SGLT2 inhibitors (empagliflozin and dapagliflozin) in heart failure with mildly preserved or preserved ejection fraction (HFpEF/HFpEF), highlighting early CV benefit in EMPEROR-Preserved and DELIVER trials, lack of consistent CV death reduction, …
DOI: 10.31579/2693-4779/114 -
Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease
This CME supplement reviews evidence that SGLT-2 inhibitors reduce heart failure and kidney outcomes in high-risk patients, and summarizes guideline-based guidance for shingles vaccination, asthma, COPD, obesity, aspirin, statins, type 1 diabetes screening, CKD, and CGM.
DOI: 10.12788/jfp.0225 -
Effect of empagliflozin on reducing the no-reflow phenomenon in patients with ST-elevation myocardial infarction: rationale and design of the EMPA-PCI trial
The EMPA-PCI trial protocol outlines a randomized, single-center study to test whether pre-procedural empagliflozin reduces the no-reflow phenomenon and reperfusion injury in STEMI patients undergoing primary PCI, using imaging, biomarker, and angiographic endpoints over a 3-mon…
DOI: 10.1093/ehjopen/oeaf128 -
A safety update on sodium glucose co‐transporter 2 inhibitors
Overall, SGLT2 inhibitors have a generally favorable safety profile with infrequent serious adverse events; genital mycotic infections are the most consistently increased adverse effect, amputation risk appears amplified mainly with canagliflozin and not consistently with other …
DOI: 10.1111/dom.13611 -
SGLT-hemlar – Nýir meðferðarmöguleikar við langvinnum nýrnasjúkdómi og hjartabilun
This narrative review concludes that SGLT2 inhibitors reduce cardiovascular and renal events in heart failure and chronic kidney disease, with benefits across ejection fractions and diabetes status, while requiring vigilance for rare ketoacidosis and Fournier gangrene.
DOI: 10.17992/lbl.2024.12.817 -
Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial
In a randomized, double-blind trial (EmDia) in adults with type 2 diabetes and elevated LV filling pressures, adding empagliflozin 10 mg daily to usual care significantly improved left ventricular diastolic function (E/e´) over 12 weeks compared with placebo, with concurrent fav…
DOI: 10.1007/s00392-023-02164-w -
Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
In a non-diabetic mouse model of pressure overload-induced heart failure, four weeks of empagliflozin improved mitochondrial function and reduced oxidative stress through direct cardiac effects, attenuating remodeling and improving cardiac function without changing blood glucose…
DOI: 10.3389/fcvm.2022.859253